A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 53
- Registration Number
- NCT03257631
- Locations
- 🇫🇷
Local Institution - 101, Villejuif CEDEX, France
🇪🇸Local Institution - 302, Barcelona, Spain
🇫🇷Local Institution - 105, Vandoeuvre les Nancy, France
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 139
- Registration Number
- NCT03220347
- Locations
- 🇮🇹
Local Institution - 302, Rozzano (MI), Italy
🇪🇸Local Institution - 202, Madrid, Spain
🇫🇷Local Institution - 102, Bordeaux, France
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 95
- Registration Number
- NCT03194542
- Locations
- 🇺🇸
Local Institution - 109, Cleveland, Ohio, United States
🇺🇸Local Institution - 100, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center The University of Texas, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 289
- Registration Number
- NCT03161483
- Locations
- 🇺🇸
North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States
🇺🇸University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 138
- Registration Number
- NCT03142191
- Locations
- 🇺🇸
Local Institution - 502, Dallas, Texas, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT03135509
- Locations
- 🇺🇸
Quintiles Phase One Services, LLC, Overland Park, Kansas, United States
A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 911
- Registration Number
- NCT03106324
- Locations
- 🇧🇪
AZ Nikolaas, Sint Niklass, Belgium
🇧🇪CHU du Mont-Godinne, Yvoir, Belgium
🇳🇱Nij Smellinghe, Drachten, Netherlands
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 80
- Registration Number
- NCT03098589
- Locations
- 🇯🇵
ASO KK Iizuka Hospital, Iizuka, Fukuoka, Japan
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT03097016
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 46
- Registration Number
- NCT03003520
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇦🇹Hanusch Krankenhaus, Wien, Austria
🇩🇰Odense Universitetshospital, Odense C, Denmark